Concepedia

Author

Cara Mathews

Women & Infants Hospital of Rhode IslandORCID

Also Known As

C Mathews, C. Mathews, C.A. Mathews, Cara A. Mathews, Cara A Mathews, Cara A. Mathews, Cara Amanda Mathews, Cara Mathews, Charlotte Mathews

243

Publications

8.3K

Citations

34

H-Index

55

Concepts

All Affiliations

Women & Infants Hospital of Rhode IslandMemorial Sloan Kettering Cancer CenterBrown UniversityProvidence CollegeUniversity of Oklahoma Health Sciences Center
CM

About

Cara Mathews is an author at Women & Infants Hospital of Rhode Island specializing in medicine, obstetrics, and gynecology oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

29

1.6K

2

Health Sciences

6

6

227

3

Public Health

2

2

320

4

Diagnostic Sciences

1

1

12

5

Immunology

1

1

16

Cara Mathews

×

58

Publications

7.6K

Citations

30

H-Index

YearCitations

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia,

New England Journal of Medicine

2018

2.7K

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

Ramez N. Eskander, Michael W. Sill, Lindsey Beffa,

New England Journal of Medicine

2023

626

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo,

Journal of Clinical Oncology

2022

432

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

Ana Oaknin, Anna V. Tinker, Lucy Gilbert,

JAMA Oncology

2020

346

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

Dmitriy Zamarin, Robert A. Burger, Michael W. Sill,

Journal of Clinical Oncology

2020

329

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

Ana Oaknin, Lucy Gilbert, Anna V. Tinker,

Journal for ImmunoTherapy of Cancer

2022

300

Performance of p16/Ki-67 Immunostaining to Detect Cervical Cancer Precursors in a Colposcopy Referral Population

Nicolas Wentzensen, Lauren M. Schwartz, Rosemary E. Zuna,

Clinical Cancer Research

2012

237

Multiple Biopsies and Detection of Cervical Cancer Precursors at Colposcopy

Nicolas Wentzensen, Joan L. Walker, Michael A. Gold,

Journal of Clinical Oncology

2014

214

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García,

The Lancet

2023

175

Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial

Linda Mileshkin, Kathleen N. Moore, Elizabeth H Barnes,

The Lancet Oncology

2023

174

Page 1